What was the overall market valuation for leukemia therapeutics in South America in 2024?

The overall market valuation for leukemia therapeutics in South America was $1693.65 Million in 2024. Read More

What is the projected market valuation for leukemia therapeutics in South America by 2035?

The projected market valuation for leukemia therapeutics in South America is $2200.0 Million by 2035. Read More

What is the expected CAGR for the South America leukemia therapeutics market during the forecast period 2025 - 2035?

The expected CAGR for the South America leukemia therapeutics market during the forecast period 2025 - 2035 is 2.41%. Read More

Which companies are the key players in the South America leukemia therapeutics market?

Key players in the South America leukemia therapeutics market include Roche, Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda, AstraZeneca, and Merck & Co. Read More

What were the revenue figures for chemotherapy in the South America leukemia therapeutics market in 2024?

In 2024, the revenue figures for chemotherapy in the South America leukemia therapeutics market ranged from $500.0 Million to $650.0 Million. Read More

How does the revenue from combination therapy compare to monotherapy in the South America leukemia therapeutics market?

The revenue from combination therapy in 2024 ranged from $800.0 Million to $1000.0 Million, whereas monotherapy ranged from $500.0 Million to $650.0 Million. Read More

What was the revenue range for intravenous administration of leukemia therapeutics in 2024?

The revenue range for intravenous administration of leukemia therapeutics in 2024 was between $800.0 Million and $1000.0 Million. Read More

What are the projected revenue figures for pediatric patients in the South America leukemia therapeutics market by 2035?

The projected revenue figures for pediatric patients in the South America leukemia therapeutics market by 2035 are expected to be between $676.82 Million and $860.0 Million. Read More

What was the revenue for immunotherapy in the South America leukemia therapeutics market in 2024?

In 2024, the revenue for immunotherapy in the South America leukemia therapeutics market ranged from $300.0 Million to $400.0 Million. Read More

What is the expected revenue range for stem cell transplant therapies in the South America leukemia therapeutics market by 2035?

The expected revenue range for stem cell transplant therapies in the South America leukemia therapeutics market by 2035 is projected to be between $300.0 Million and $350.0 Million. Read More

South America Leukemia Therapeutics Market

ID: MRFR/HC/52107-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

South America Leukemia Therapeutics Market Research Report: Size, Share, Trend Analysis By Drug Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplant, Radiation Therapy), By Therapy Type (Monotherapy, Combination Therapy, Maintenance Therapy), By Administration Route (Oral, Intravenous, Subcutaneous), By Patient Type (Adult, Pediatric) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

South America Leukemia Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Drug Type (USD Million)
  1. 4.1.1 Chemotherapy
  2. 4.1.2 Targeted Therapy
  3. 4.1.3 Immunotherapy
  4. 4.1.4 Stem Cell Transplant
  5. 4.1.5 Radiation Therapy
2. 4.2 Industrial Automation & Equipment, BY Therapy Type (USD Million)
  1. 4.2.1 Monotherapy
  2. 4.2.2 Combination Therapy
  3. 4.2.3 Maintenance Therapy
3. 4.3 Industrial Automation & Equipment, BY Administration Route (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Intravenous
  3. 4.3.3 Subcutaneous
4. 4.4 Industrial Automation & Equipment, BY Patient Type (USD Million)
  1. 4.4.1 Adult
  2. 4.4.2 Pediatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Gilead Sciences (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Celgene (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Takeda (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY THERAPY TYPE
4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPY TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPY TYPE, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT TYPE, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY THERAPY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South America Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Drug Type (USD Million, 2025-2035)

Chemotherapy
Targeted Therapy
Immunotherapy
Stem Cell Transplant
Radiation Therapy

Industrial Automation & Equipment By Therapy Type (USD Million, 2025-2035)

Monotherapy
Combination Therapy
Maintenance Therapy

Industrial Automation & Equipment By Administration Route (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Industrial Automation & Equipment By Patient Type (USD Million, 2025-2035)

Adult
Pediatric

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”